China Biologic Products

China Biologic Products, Inc. is a China-focused biopharmaceutical company whose business centers on the research, manufacture, and sale of plasma-derived human medicines. Its operations have been conducted through Shandong Taibang, an indirect majority-owned subsidiary and a blood-products producer approved by the government of Shandong Province. The company’s principal commercial scope is the collection or sourcing of plasma and its processing into pharmaceutical products used in clinical care. Its product area is based on human plasma rather than conventional small-molecule drugs. Plasma-derived human albumin is used primarily to expand or restore blood volume in medical settings. Immunoglobulin products are used for disease prevention and treatment, including applications in which antibody-based therapy or immune support is clinically indicated. The company’s customers include hospitals and other healthcare institutions in China. China Biologic Products operated as a public company on Nasdaq before a major ownership transition. In April 2021, an investor consortium including Centurium Capital, CITIC Capital, and Hillhouse Capital completed a reported $4.6 billion take-private transaction. The transaction changed the company’s listed-market status and ownership structure, but the available reference material does not provide sufficient detail to identify its subsequent legal structure, current ownership percentages, present headquarters, or current management. The company occupies a specialized position in China’s biologics and blood-products sector. Plasma-derived products require access to approved plasma-collection infrastructure, specialized manufacturing capabilities, quality controls, and regulatory authorization. These characteristics distinguish the business from general pharmaceutical branding and create a comparatively focused operating model centered on biologic raw materials and hospital distribution. Based on the available material, its principal geographic market is China, and no reliable information is provided here to establish a broader international commercial footprint.

China Biologic Products developed as a China-focused biopharmaceutical business specializing in medicines derived from human blood plasma. Through its indirect majority-owned subsidiary Shandong Taibang, the company conducted research, manufacturing, and commercial distribution of plasma-based products for hospitals and other healthcare facilities. Shandong Taibang is identified in the available reference material as the only blood plasma-based biopharmaceutical company approved by the government of Shandong Province. The company’s operating model is built around the specialized processing of plasma into therapeutic products. Human albumin is used principally in clinical situations requiring blood-volume expansion or restoration. Immunoglobulins provide antibody-based products used in disease prevention and treatment. These products place the company within the regulated biologics and blood-products segment rather than the broader consumer-health or conventional pharmaceutical categories. China Biologic Products was previously listed on Nasdaq. Its most significant documented ownership event occurred in April 2021, when an investor consortium involving Centurium Capital, CITIC Capital, and Hillhouse Capital took the company private in a reported transaction valued at $4.6 billion. This transaction marked the end of its public-market listing and represented a major change in corporate ownership. The supplied references do not establish the company’s founding year, original founders, current corporate parent, present executives, or post-transaction operating structure, so those details remain unreported here. The available information indicates that the company’s principal business and customer base are located in China. Its competitive and regulatory position depends on access to plasma-based raw materials, licensed collection and processing capacity, product-quality systems, and authorization to supply healthcare institutions. No additional reliable source material is provided for a fuller chronology of acquisitions, product launches, regulatory actions, campaigns, or changes in manufacturing footprint.

1. 2021Take-private transaction completed

   An investor group including Centurium Capital, CITIC Capital, and Hillhouse Capital completed a reported $4.6 billion transaction that took China Biologic Products private and ended its Nasdaq listing.

   Source

A China-focused plasma-derived biopharmaceutical company serving hospitals and healthcare facilities with human albumin, immunoglobulins, and related blood-plasma products.

• Human albuminPlasma-derived biologic

  A plasma-derived pharmaceutical product used mainly to increase or restore circulating blood volume in hospital and other clinical-care settings. It is one of the company’s principal described product categories.

• ImmunoglobulinPlasma-derived biologic

  Antibody-containing plasma-derived products used for disease prevention and treatment. The available reference identifies immunoglobulin as a core product area, but does not specify individual formulations, indications, or brand names.

• 2021Decision to complete a take-private transactionM&A

  China Biologic Products was previously a Nasdaq-listed company. In April 2021, an investor consortium including Centurium Capital, CITIC Capital, and Hillhouse Capital pursued and completed a transaction to acquire the company.

  What changed. The investor group completed the take-private transaction, reported at approximately $4.6 billion, removing the company from public Nasdaq trading.

  Aftermath. The transaction changed the company from a Nasdaq-listed public company into a privately held business. The supplied references do not provide reliable details about its subsequent ownership structure or operating performance.

  Reported transaction value. $4.6 billion transaction value (April 2021)

  Source

• 2021China Biologic Products taken private in reported $4.6 billion transaction

  An investor group including Centurium Capital, CITIC Capital, and Hillhouse Capital completed a transaction to take China Biologic Products private, ending its Nasdaq-listed status.

  M&AOther
  Source

1. China Biologic Products